Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).

Salvi F, Luminari S, Tucci A, Massidda S, Liberati AM, Stelitano C, Zanni M, Re A, Centurioni R, Freilone R, Musuraca G, Nassi L, Patti C, Arcari A, Tani M, Pulsoni A, Pavone V, Volpetti S, Peli A, Evangelista A, Spina M, Ladetto M, Merli F.

Leuk Lymphoma. 2019 Jul 8:1-9. doi: 10.1080/10428194.2019.1608529. [Epub ahead of print]

PMID:
31282794
2.

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C.

Br J Haematol. 2018 Dec;183(5):755-765. doi: 10.1111/bjh.15641. Epub 2018 Nov 8.

PMID:
30407629
3.

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.

Ambrosio MR, Lazzi S, Bello GL, Santi R, Porro LD, de Santi MM, Guazzo R, Mundo L, Rigacci L, Kovalchuck S, Onyango N, Fabbri A, Cencini E, Zinzani PL, Zaja F, Angrilli F, Stelitano C, Cabras MG, Spataro G, Bob R, Menter T, Granai M, Cevenini G, Naresh KN, Stein H, Sabattini E, Leoncini L.

Haematologica. 2019 Jan;104(1):e25-e28. doi: 10.3324/haematol.2018.195958. Epub 2018 Jun 28. No abstract available.

4.

Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M.

J Clin Oncol. 2018 Mar 1;36(7):689-696. doi: 10.1200/JCO.2017.74.1652. Epub 2017 Nov 2.

PMID:
29095677
5.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.

Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

PMID:
28668386
6.

Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.

Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri AJM, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Giovanella L, Zucca E, Johnson PWM.

Br J Haematol. 2017 Aug;178(4):588-591. doi: 10.1111/bjh.14728. Epub 2017 May 9.

PMID:
28485042
7.

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C.

J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29. Erratum in: J Clin Oncol. 2017 Jul 10;35(20):2342.

PMID:
28355112
8.

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.

Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, Rocco AD, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldero G, Nonis A, Scarfò L, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M.

Lancet Haematol. 2017 Mar;4(3):e137-e146. doi: 10.1016/S2352-3026(17)30016-9. Epub 2017 Feb 17.

PMID:
28219694
9.

A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy.

Tuscano C, Vincelli ID, Arico' D, Marchione AM, Versace P, Stelitano C, Porta N, Petrozza V, Di Cristofano C, Sceni G, Ronco F, Russi EG, Al Sayyad S.

Adv Radiat Oncol. 2017 Jan 25;3(2):121-124. doi: 10.1016/j.adro.2017.01.007. eCollection 2018 Apr-Jun. No abstract available.

10.

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarello E, Ladetto M, Carmichael J, Fanin R.

Haematologica. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211. Epub 2017 Jan 12. No abstract available.

11.

Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.

Ceriani L, Martelli M, Gospodarowicz MK, Ricardi U, Ferreri AJ, Chiappella A, Stelitano C, Balzarotti M, Cabrera ME, Cunningham D, Guarini A, Zinzani PL, Giovanella L, Johnson PW, Zucca E.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):42-49. doi: 10.1016/j.ijrobp.2016.09.031. Epub 2016 Sep 28.

PMID:
27839910
12.

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.

Bari A, Marcheselli R, Marcheselli L, Alvarez I, Pozzi S, Ferri P, Lazzaro A, Fragasso A, Neri S, Baldini L, Carella AM, Angrilli F, Guariglia R, Buda G, Stelitano C, Sacchi S; Gruppo Italiano Studio Linfomi (GISL).

Acta Haematol. 2017;137(1):7-14. doi: 10.1159/000449052. Epub 2016 Nov 4.

13.

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.

Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, Romano A, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Małkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA.

Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.

PMID:
27692305
14.

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Afanasyev B, Kaplanov K, Thyss A, Kuzmin A, Voloshin S, Kuliczkowski K, Giza A, Milpied N, Stelitano C, Marks R, Trümper L, Biyukov T, Patturajan M, Bravo ML, Arcaini L; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network.

Lancet Oncol. 2016 Mar;17(3):319-31. doi: 10.1016/S1470-2045(15)00559-8. Epub 2016 Feb 16.

PMID:
26899778
15.

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A.

J Clin Oncol. 2016 Apr 20;34(12):1376-85. doi: 10.1200/JCO.2015.63.0699. Epub 2016 Feb 16.

16.

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).

Balzarotti M, Brusamolino E, Angelucci E, Carella AM, Vitolo U, Russo E, Congiu A, Gotti M, Massidda S, Botto B, Annechini G, Spina M, Re A, Zilioli VR, Merli F, Salvi F, Stelitano C, Bonfichi M, Rodari M, Murru R, Magagnoli M, Anastasia A, Mazza R, Giordano L, Santoro A.

Leuk Lymphoma. 2016 Oct;57(10):2375-81. doi: 10.3109/10428194.2016.1140161. Epub 2016 Feb 15.

PMID:
26879066
17.

Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).

Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A.

Br J Haematol. 2016 Mar;172(6):879-88. doi: 10.1111/bjh.13904. Epub 2016 Jan 13.

PMID:
26763986
18.

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M.

J Clin Oncol. 2016 Apr 10;34(11):1175-81. doi: 10.1200/JCO.2015.62.4817. Epub 2015 Dec 28.

PMID:
26712220
19.

A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, Salvi F, Arcaini L, Carella AM, Tedeschi A, Pinto A, Stelitano C, Baldini L.

Leuk Lymphoma. 2016;57(4):880-7. doi: 10.3109/10428194.2015.1091934. Epub 2016 Feb 8.

PMID:
26379040
20.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli F, Pinotti G, Mannina D, Luminari S, Stathis A, Russo E, Cavalli F, Giovanella L, Johnson PW, Zucca E.

Blood. 2015 Aug 20;126(8):950-6. doi: 10.1182/blood-2014-12-616474. Epub 2015 Jun 18.

PMID:
26089397
21.

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.

Iannitto E, Luminari S, Tripodo C, Mancuso S, Cesaretti M, Marcheselli L, Merli F, Stelitano C, Carella AM, Fragasso A, Montechiarello E, Ricciuti G, Pulsoni A, Paulli M, Franco V, Federico M.

Leuk Lymphoma. 2015;56(12):3281-7. doi: 10.3109/10428194.2015.1029925. Epub 2015 Jul 18.

PMID:
25791121
22.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

23.

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.

Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA.

Haematologica. 2015 Apr;100(4):517-24. doi: 10.3324/haematol.2014.108183. Epub 2015 Jan 16.

24.

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).

Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M; Italian Lymphoma Foundation (FIL).

Leuk Lymphoma. 2015 Apr;56(4):921-6. doi: 10.3109/10428194.2014.953142. Epub 2014 Oct 9.

PMID:
25110825
25.

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Davies A, Cavalli F, Giovanella L, Johnson PW.

J Clin Oncol. 2014 Jun 10;32(17):1769-75. doi: 10.1200/JCO.2013.51.7524. Epub 2014 May 5.

PMID:
24799481
26.

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A.

Ann Oncol. 2014 Jul;25(7):1404-10. doi: 10.1093/annonc/mdu166. Epub 2014 May 5.

PMID:
24799461
27.

MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.

Ferreri AJ, Ciceri F, Brandes AA, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Reni M.

Neurology. 2014 Apr 15;82(15):1370-3. doi: 10.1212/WNL.0000000000000314. Epub 2014 Mar 14.

PMID:
24634458
28.

Survival and Prognostic Factors for AIDS and Non-AIDS Patients with Non-Hodgkin's Lymphoma in Bahia, Brazil: A Retrospective Cohort Study.

Luz E, Marques M, Luz I, Stelitano C, Netto E, Araújo I, Brites C.

ISRN Hematol. 2013 Oct 29;2013:904201. doi: 10.1155/2013/904201. eCollection 2013.

29.

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.

Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D'Arco AM, Musto P, Chiappella A, Baldini L, Bonfichi M, Arcaini L.

Haematologica. 2014 Mar;99(3):489-96. doi: 10.3324/haematol.2013.094318. Epub 2013 Nov 22.

30.

Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy.

Merlini L, Cartenì G, Iacobelli S, Stelitano C, Airoldi M, Balcke P, Keil F, Haslbauer F, Belton L, Pujol B.

Cancer Manag Res. 2013 Aug 2;5:205-14. doi: 10.2147/CMAR.S45236. eCollection 2013.

31.

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.

Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M.

J Clin Oncol. 2013 Apr 20;31(12):1506-13. doi: 10.1200/JCO.2012.45.0866. Epub 2013 Mar 25. Erratum in: J Clin Oncol. 2014 Apr 1;32(10):1095. Dosage error in article text.

PMID:
23530110
32.

Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi.

Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A, Spina M, Tucci A, Stelitano C, Capodanno I, Fragasso A, Baldini L, Bottelli C, Montechiarello E, Fogazzi S, Lamorgese C, Cavalli L, Federico M; Fondazione Italiana Linfomi.

Leuk Lymphoma. 2014 Jan;55(1):38-43. doi: 10.3109/10428194.2013.788176. Epub 2013 Apr 30.

PMID:
23517562
33.

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

Corazzelli G, Angrilli F, D'Arco A, Ferrara F, Musto P, Guarini A, Cox MC, Stelitano C, Storti S, Iannitto E, Falorio S, Califano C, Amore A, Arcamone M, De Filippi R, Pinto A.

Br J Haematol. 2013 Jan;160(2):207-15. doi: 10.1111/bjh.12120. Epub 2012 Nov 20.

PMID:
23167437
34.

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.

Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.

Hematol Oncol. 2013 Sep;31(3):143-50. doi: 10.1002/hon.2037. Epub 2012 Nov 14.

PMID:
23161567
35.

Mycosis fungoides: disease evolution of the "lion queen" revisited.

Quaglino P, Pimpinelli N, Berti E, Calzavara-Pinton P, Lombardo GA, Rupoli S, Alaibac M, Arcaini L, Bagnato S, Baldo A, Bottoni U, Carbone A, Cestari R Clerico R, De Renzo A, Fava P, Fierro MT, Filotico R, Fimiani M, Frontani M Girgenti V, Goteri G, Leali C, Mamusa AM, Mariotti G, Mastrandrea V, Pellegrini C, Pennese E, Pileri A, Savoia P, Stelitano C, Titli S, Virgili A, Zichichi L, Zinzani PL, Bernengo MG.

G Ital Dermatol Venereol. 2012 Dec;147(6):523-31. Review.

PMID:
23149698
36.

Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.

Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R.

J Clin Oncol. 2012 Aug 20;30(24):2988-94. doi: 10.1200/JCO.2011.41.4466. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903.

PMID:
22802315
37.

Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters.

Gobbi PG, Bergonzi M, Bassi E, Merli F, Coriani C, Stelitano C, Iannitto E, Federico M.

Oncol Rep. 2012 Sep;28(3):815-20. doi: 10.3892/or.2012.1892. Epub 2012 Jun 29.

PMID:
22752083
38.

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.

Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, Cesaretti M, Rossi A, Rigacci L, Gaidano G, Merli F, Spina M, Stelitano C, Hohaus S, Barbui A, Puccini B, Miranda EC, Guida A, Federico M.

Leuk Lymphoma. 2013 Jan;54(1):53-7. doi: 10.3109/10428194.2012.691482. Epub 2012 Sep 28.

PMID:
22712840
39.

Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.

Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L.

Cancer. 2012 Aug 15;118(16):3954-61. doi: 10.1002/cncr.26708. Epub 2011 Dec 16.

40.

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.

Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, Stelitano C, Caracciolo F, Di Renzo N, Angrilli F, Carella AM, Capodanno I, Barbolini E, Galimberti S, Federico M.

Br J Haematol. 2012 Feb;156(3):346-53. doi: 10.1111/j.1365-2141.2011.08958.x. Epub 2011 Dec 7.

PMID:
22145911
41.

Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.

Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.

J Clin Oncol. 2011 Nov 10;29(32):4227-33. doi: 10.1200/JCO.2010.30.9799. Epub 2011 Oct 11.

PMID:
21990405
42.

Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays.

Ciccone M, Agostinelli C, Rigolin GM, Piccaluga PP, Cavazzini F, Righi S, Sista MT, Sofritti O, Rizzotto L, Sabattini E, Fioritoni G, Falorio S, Stelitano C, Olivieri A, Attolico I, Brugiatelli M, Zinzani PL, Saccenti E, Capello D, Negrini M, Cuneo A, Pileri S.

Leukemia. 2012 Mar;26(3):499-508. doi: 10.1038/leu.2011.247. Epub 2011 Sep 23.

PMID:
21941366
43.

Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial.

Morabito F, Hohaus S, Mammi C, Marcheselli L, Gentile M, Merli F, Montanini A, Stelitano C, La Sala A, Scalone R, Voso MT, Luminari S, Iannitto E, Gobbi P, Federico M.

Leuk Lymphoma. 2012 Mar;53(3):406-10. doi: 10.3109/10428194.2011.623254.

PMID:
21916526
44.

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.

Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M.

Leuk Lymphoma. 2012 Apr;53(4):581-8. doi: 10.3109/10428194.2011.621565. Epub 2011 Nov 15.

PMID:
21895543
45.

Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.

Gobbi PG, Valentino F, Bassi E, Coriani C, Merli F, Bonfante V, Marchianò A, Gallamini A, Bolis S, Stelitano C, Levis A, Federico M, Angrilli F, Di Giulio G, Corazza GR.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):396-402. doi: 10.1016/j.clml.2011.04.008. Epub 2011 Jun 12.

PMID:
21729691
46.

Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.

Ferreri AJ, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M.

Oncologist. 2011;16(3):336-41. doi: 10.1634/theoncologist.2010-0361. Epub 2011 Feb 23.

47.

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.

Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, Cantonetti M, Stelitano C, Feldman T, Gavarotti P, Sorasio R, Mulè A, Leone M, Rambaldi A, Biggi A, Barrington S, Fallanca F, Ficola U, Chauvie S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi (GITIL).

Br J Haematol. 2011 Mar;152(5):551-60. doi: 10.1111/j.1365-2141.2010.08485.x. Epub 2010 Dec 20.

PMID:
21166786
48.

Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).

Ferrario A, Merli F, Luminari S, Stelitano C, Mannina D, Russo M, Mazza P, Marcheselli L, Goldaniga MC, Federico M, Baldini L; Gruppo Italiano per lo Studio dei Linfomi.

Ann Hematol. 2011 Mar;90(3):323-30. doi: 10.1007/s00277-010-1067-1. Epub 2010 Sep 17.

PMID:
20848104
49.

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).

Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S, Mancuso S, De Paolis MR, Plati C, Stelitano C, Patti C, Olivieri A, Liardo E, Buda G, Cantaffa R, Federico M.

Support Care Cancer. 2011 Oct;19(10):1505-10. doi: 10.1007/s00520-010-0974-y. Epub 2010 Aug 8.

50.

Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.

Mannina D, Luminari S, Dondi A, Polimeno G, Baldini L, Stelitano C, Merli F, Dell'Olio M, Gobbi PG, Giglio G, Barbolini E, Brugiatelli M, Federico M.

Leuk Lymphoma. 2010 Mar;51(3):422-9. doi: 10.3109/10428190903518352.

PMID:
20038237

Supplemental Content

Loading ...
Support Center